VERV Live signaler | Maksimer profitt med Getagraph.com

SELG 112910 min ago

@ $12.71

Utstedt: 14 feb 2024 @ 20:22

Avkastning: -51.61%

Forrige signal: feb 14 - 18:04

Forrige signal: Kjøp

Avkastning: 0.87 %

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Stats
Dagens volum	928 599
Gjennomsnittsvolum	1.32M
Markedsverdi	483.08M
EPS	$0 ( 2024-03-07 )
Neste inntjeningsdato	( $-0.680 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.970
ATR14	$0.0100 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Nickerson Joan	Buy	3 315	Common Stock
2024-04-01	Nickerson Joan	Sell	3 315	Restricted Stock Units
2024-04-02	Nickerson Joan	Sell	1 514	Common Stock
2024-02-14	Ashe Andrew D.	Buy	150 000	Stock Option (right to buy)
2024-02-14	Ashe Andrew D.	Buy	36 000	Restricted Stock Units

INSIDER POWER
78.77
Last 97 transactions
Buy: 4 843 517 \| Sell: 1 394 833

Volum Korrelasjon

Lang: -0.26 (neutral)

Kort: -0.24 (neutral)

Signal:(61.157) Neutral

Verve Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
SVOK	0.939
BIOL	0.915
ARVN	0.9
TSP	0.886
TIL	0.885
UK	0.884
YMAB	0.88
AVCT	0.879
FCACU	0.874
TFFP	0.873

10 Mest negative korrelasjoner
BOCH	-0.93
SHSP	-0.897
LMRK	-0.881
QADA	-0.877
VLYPO	-0.863
RAVN	-0.852
NETE	-0.84
MMSI	-0.837
NRIM	-0.836
MDLZ	-0.83

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Verve Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.01
( neutral )

-0.31
( neutral )

0.00
( neutral )

0.16
( neutral )

-0.23
( neutral )

Verve Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$11.76M
Bruttogevinst:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2023
Omsetning:	$11.76M
Bruttogevinst:	$6.30M (53.61 %)
EPS:	$-3.12

FY	2022
Omsetning:	$1.94M
Bruttogevinst:	$-4.77M (-245.75 %)
EPS:	$-2.91

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-6.78

Financial Reports:

No articles found.

Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.